Almirall Shares Real-World Data at 2025 International Congress of Dermatology

Image Credit: © Timon - stock.adobe.com

At last week’s International Congress of Dermatology (ICD) held in Rome, Italy, Almirall shared real-world data on atopic dermatitis (AD), psoriasis, and actinic keratosis (AK).¹ Information was presented through posters and scientific symposia.

“Our participation in the International Congress of Dermatology reflects Almirall’s continuous focus on advancing science and innovation in medical dermatology. Our close collaborations and partnerships with dermatologists and healthcare professionals around the world are a cornerstone for our dedication to delivering meaningful solutions that improve patients’ lives. The ICD offers an important opportunity to collectively push the boundaries of science and advance the standards of care in dermatology,” Volker Koscielny, MD, MBA, Almirall’s Chief Medical Officer, said in a press release.¹

Scientific Contributions

Results from the ADvocate 1 and 2 monotherapy trials were shared, emphasizing the effectiveness of lebrikizumab over time in patients with moderate to severe AD. The ADvantage clinical trial further supported these findings, showing that when combined with topical corticosteroids, lebrikizumab significantly improved signs and symptoms of AD in adults and adolescents with moderate to severe disease at weeks 16 and 52.

Interim results of the POSITIVE study, the first dermatological clinical study to use the WHO-5 Well-being Index as a primary endpoint, were also presented.² Patients with moderate to severe plaque psoriasis who were treated with tildrakizumab observed improved psychological well-being. The TIRBASKIN study was highlighted as well, focusing on the improvements of symptoms, emotions, functioning, and overall quality of life for patients with AKs after taking tirbanibulin. An 83% mean AK lesion count reduction was noted from baseline to day 57.

Symposia Insights

The first symposium, titled “Integrating Patient Voices and Treatment Advances in AD,” was led by experts Ignasi Figueras Nart, MD; Andreas Pinter, MD; and Silvia Ferrucci, MD. The session focused on the real-world impact of treatment, highlighting research pearls and clinical approaches for patient-centered care.

“The ICD offers a fantastic opportunity to share clinical experiences, both diagnostic and therapeutic, especially concerning inflammatory skin diseases. During the Almirall symposium, we will discuss the real-life Italian experience with a new monoclonal antibody targeting IL-13 for moderate to severe atopic dermatitis. The real-life results are consistent with, or even surpass, those observed in registration studies, both in terms of disease signs and patient-reported outcomes,” Ferrucci said in a statement.¹

The second symposium, titled “Are the Difficult-to-Treat Patients with Psoriasis Still Difficult to Treat?” was led by Nina Magnolo, MD, and Anna Campanati, MD. The clinicians touched upon difficult-to-treat areas in psoriasis management and how patient quality of life can be impacted. Additionally, phase 3b trial results of tildrakizumab were presented, confirming the IL-23 inhibitor’s use in cases of scalp psoriasis.

“Patients with psoriasis experience worse burden of disease when difficult-to-treat areas are affected. It is essential that we continue to elevate awareness and tailor our treatment strategies to address specific challenges. By focusing on hard-to-treat areas and presenting new clinical evidence, we aim to empower clinicians with insights that can meaningfully improve patient outcomes,” Magnolo said.¹

The company also announced initiatives like the PsOlve Challenge and the Sanctuary Salon. The selected project from the PsOlve Challenge was chosen out of 25 proposals from academic and healthcare institutions across Italy, France, Germany, and Spain, emphasizing holistic approaches to long-term psoriasis care. Furthermore, the Sanctuary Salon educated attendees on skin conditions like psoriasis, atopic dermatitis, and actinic keratosis, especially in the scalp area, and how these can influence daily life and self-care habits.

References

1. Almirall shows efficacy of biologics with real-world evidence and new patient-centric research on psychological wellbeing at the 2025 International Congress of Dermatology. News Release. Almirall. June 19, 2025. Accessed June 26, 2025. https://www.almirall.com/newsroom/news/almirall-shows-efficacy-of-biologics-with-real-world-evidence-and-new-patient-centric-research-on-psychological-wellbeing-at-the-2025-international-congress-of-dermatology

2. Almirall leads a paradigm shift to holistic patient care in dermatology, applying the WHO-5 well-being index as primary endpoint in clinical trials. News Release. Almirall. June 4, 2025. Accessed June 26, 2025. https://www.almirall.com/newsroom/news/almirall-leads-a-paradigm-shift-to-holistic-patient-care-in-dermatology-applying-the-who-5-well-being-index-as-primary-endpoint-in-clinical-trials